About this episode

The episode discusses the potential of mesenchymal stromal cells as a therapeutic option for COVID-19-induced acute respiratory distress syndrome based on recent clinical trials.

Acute respiratory distress syndrome (ARDS) induced by COVID-19 was a leading cause of severe illness and death during the pandemic, driven by an intense innate immune response, hyperinflammation, and a decrease in lymphocytes. Mesenchymal stromal cells (MSCs) represent a potential therapeutic option for ARDS due to their ability to modulate the immune system and inflammation. Our guests report results from a Health Canada–regulated Phase I and Phase II trials evaluating freshly cultured umbil...

People in this episode

Host: Janet Rossant

Topics covered

• COVID-19
• acute respiratory distress syndrome
• therapeutic strategies

Mentioned in this episode

Organizations: Health Canada

Products: mesenchymal stromal cells

Places: COVID-19

More episodes of The Stem Cell Report with Janet Rossant

• Making Sense of Touch · March 9, 2026 · 46 min
• Illuminating hPSC-derived Sensory Neurons · February 10, 2026 · 35 min
• Tuning the X · January 22, 2026 · 43 min
• Building a Better Barrier: Modeling the Human Gut Epithelium · November 19, 2025 · 43 min
• Crossing the Border: Modeling the Blood Brain Barrier · October 23, 2025 · 30 min
• Movin’ On Out: Mobilizing HSCs From The Bone Marrow · September 22, 2025 · 33 min

Explore listener stats, chart rankings, contacts and more on the The Stem Cell Report with Janet Rossant podcast page.